Russia To Test ‘Sputnik V’ COVID-19 Vaccine In 40K Human Subjects
The Russian government said Thursday it will begin clinical trials next week for its already-registered COVID-19 vaccine and it will involve tens of thousands of human subjects.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, told reporters the trials will be done in several countries, including Russia, Saudi Arabia and the United Arab Emirates. He said the trials will involve 40,000 humans.
Dmitriev also said Russia hopes to have detailed scientific data published in a major journal sometime this month.
Russian President Vladimir Putin announced earlier this month that Moscow had registered the "Sputnik V" vaccine and said he'd even administered it to one of his daughters. The announcement was met with surprise and skepticism in the medical community, as the vaccine had not been put through late-stage clinical trials, which is a key phase for any vaccine development.
The World Health Organization said Thursday it has begun discussions with Russia about testing the vaccine.
"This concern that we have around safety and efficacy is not specifically for the Russia vaccine, it's for all of the vaccines under development," said Catherine Smallwood, WHO Europe's senior emergency official. "It's essential we don't cut corners in safety or efficacy."
"The end of the pandemic will be the day when everyone of us will take the responsibility and have been learning how to behave with the virus," WHO Europe Regional Director Hans Kluge cautioned. "And that depends on us, that day can even be tomorrow."
Moscow has not yet released any scientific data associated with the Sputnik V vaccine and most experts continue to be skeptical of its safety or ability to ward off the coronavirus.



Survey Shows Biggest Jump In Investor Optimism Since March 2020
Dow Jones Lags As Jobless Claims Spike, But Nasdaq Eyes New Closing High
Advisor News
- Equitable launches 403(b) pooled employer plan to support nonprofits
- Financial FOMO is quietly straining relationships
- GDP growth to rebound in 2027-2029; markets to see more volatility in 2026
- Health-related costs are the greatest threat to retirement security
- Social Security literacy is crucial for advisors
More Advisor NewsAnnuity News
- Best’s Special Report: Analysis Shows Drastic Shift in Life Insurance Reserves Toward Annuity Products, and a Slide in Credit Quality
- MetLife to Announce First Quarter 2026 Results
- CT commissioner: 70% of policyholders covered in PHL liquidation plan
- ‘I get confused:’ Regulators ponder increasing illustration complexities
- Three ways the Corebridge/Equitable merger could shake up the annuity market
More Annuity NewsHealth/Employee Benefits News
- Health care in America should be redesigned
Op-ed: We should redesign health care in America. Here's a plan that would help Nebraskans (copy)
- Humana and Thor hit the Casualty List, can revive and thrive
Humana and Thor Hit the Casualty List
- Pols & Politics: Romney, Patrick, Dukakis, Weld, and Healey to celebrate 20 years of MassHealth
- Homage names Allan Fisher as director of administration and strategy
- Illinoisans to pay for other’s abortion services under proposed grant program
More Health/Employee Benefits NewsLife Insurance News
- An Application for the Trademark “PREMIER ACCESS” Has Been Filed by The Guardian Life Insurance Company of America: The Guardian Life Insurance Company of America
- AM Best Assigns Credit Ratings to North American Fire & General Insurance Company Limited and North American Life Insurance Company Limited
- Supporting the ‘better late than never’ market with life insurance
- Best’s Special Report: Analysis Shows Drastic Shift in Life Insurance Reserves Toward Annuity Products, and a Slide in Credit Quality
- The child-free client: how advisors can support this growing demographic
More Life Insurance News